A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

ClinicalTrials.gov ID: NCT00111007

Public ClinicalTrials.gov record NCT00111007. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 9:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase III Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination With Paclitaxel/Carboplatin Chemotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objectives of this study are to compare the anti-tumor activity as measured by Progression Free Survival (PFS) and tolerability of Sorafenib in combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in combination with placebo in subjects with unresectable Stage III or Stage IV melanoma who progressed after receiving only one prior therapy containing Dacarbazine (DTIC) or Temozolomide (TMZ).

Study identification

NCT ID: NCT00111007
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bayer; Industry
Enrollment: 270 participants

Conditions and interventions

Conditions

Melanoma

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 30, 2005
Primary completion: Aug 31, 2006
Completion: Dec 31, 2008
Last update posted: Oct 30, 2014

2005 – 2009

United States locations

U.S. sites: 19
U.S. states: 17
U.S. cities: 19

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35243	—
Not listed	Tucson	Arizona	85724	—
Not listed	Los Angeles	California	90025	—
Not listed	Aurora	Colorado	80045	—
Not listed	Tampa	Florida	33612	—
Not listed	Chicago	Illinois	60612	—
Not listed	Park Ridge	Illinois	60068	—
Not listed	Louisville	Kentucky	40202	—
Not listed	St Louis	Missouri	63110	—
Not listed	Omaha	Nebraska	68114	—
Not listed	Montclair	New Jersey	07042	—
Not listed	Buffalo	New York	14263	—
Not listed	New York	New York	10065	—
Not listed	Columbus	Ohio	43221	—
Not listed	Pittsburgh	Pennsylvania	15232	—
Not listed	Nashville	Tennessee	37232-6307	—
Not listed	Houston	Texas	77030	—
Not listed	Charlottesville	Virginia	22908	—
Not listed	Seattle	Washington	98109-1023	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00111007, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 30, 2014 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00111007 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →